Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Telix Pharmaceuticals
Biotech
Novartis secures new radioligand in $900M deal
Novartis licensed a preclinical radioligand from a Chinese biotech the day after Telix announced plans to buy Novartis' isotope supplier ITM.
Darren Incorvaia
Sep 22, 2026 1:22pm
Telix beams into Novartis’ territory with $1.6B ITM acquisition
Sep 21, 2026 5:19am
FDA approves Pixclara, the first FET-PET drug for brain cancer
Sep 15, 2026 7:40am
ASCO: Telix tees up pivotal test for Pluvicto challenger
Jun 1, 2026 4:12pm
Regeneron rides into radiopharma via $2.1B biobucks Telix pact
Apr 13, 2026 7:24am
Heidelberg to ax 75% of staff after milestone becomes millstone
Sep 25, 2025 7:20am
